Murine xenograft SF7796 exhibits properties similar to the bevacizumab-evasive glioblastoma from which it is derived.(A) Pre- and postcontrast murine MRI shows that SF7796 exhibits nodular enhancement (upper row left), and elevated fractional blood volume (FBV) and elevated permeability (PS) on color maps (upper row right), unusual for a murine xenograft. The enhancing tumor volume, elevated fractional blood volume, and permeability did not change after treating SF7796 with B20, an antibody that neutralizes murine and human VEGF. (B) Measurement of FBV and PS in control- and B20-treated intracranial murine SF7796 xenografts, showing no change in these parameters after B20 treatment (P=0.8) SF7796 is thus evasive to B20 treatment and is thus a xenograft model for studying treatments targeting tumors evasive to anti-angiogenic therapy, one of the goals of the research in the Aghi laboratory.